Metraipolis › archive › dc_05f990eadc00

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients — Europe PMC PMID:42416063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42416063
DOI
10.3389/fimmu.2026.1722204
License (as archived)
solo-consultazione
Archived
2026-10-19T06:11:59.841Z
SHA-256 of the archived text
59c83cdbf44d2de5e28a2c44a3b3165dfb3ec84ccd85751243d21a2326f54b2b
Stable URL of this page
https://metraipolis.com/documento/dc_05f990eadc00

How to cite

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients — Europe PMC PMID:42416063 — Europe PMC (en), https://europepmc.org/article/MED/42416063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_05f990eadc00 (Metraipolis archive dc_05f990eadc00, sha256 59c83cdbf44d2de5e28a2c44a3b3165dfb3ec84ccd85751243d21a2326f54b2b)
BibTeX
@misc{dc05f990eadc00,
  title = {Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients — Europe PMC PMID:42416063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42416063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_05f990eadc00; sha256 59c83cdbf44d2de5e28a2c44a3b3165dfb3ec84ccd85751243d21a2326f54b2b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42416063. Agents can read the archived copy with the MCP tool read_document.